Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes

Alberto Grossi, Pellegrino Musto, Valeria Santini, Francesca Balestri, Alberto Fabbri, Antonietta Falcone, Grazia Sanpaolo

Research output: Contribution to journalArticlepeer-review

Abstract

Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

Original languageEnglish
Pages (from-to)322-323
Number of pages2
JournalHaematologica
Volume87
Issue number3
Publication statusPublished - 2002

Keywords

  • Amifostine
  • MDS
  • Myelodysplastic syndromes
  • RHuEPO

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this